AU2011256098A1 - Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas - Google Patents

Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas Download PDF

Info

Publication number
AU2011256098A1
AU2011256098A1 AU2011256098A AU2011256098A AU2011256098A1 AU 2011256098 A1 AU2011256098 A1 AU 2011256098A1 AU 2011256098 A AU2011256098 A AU 2011256098A AU 2011256098 A AU2011256098 A AU 2011256098A AU 2011256098 A1 AU2011256098 A1 AU 2011256098A1
Authority
AU
Australia
Prior art keywords
drr
cells
expression
antisense
glioma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011256098A
Other languages
English (en)
Inventor
Masad Damha
Glen Deleavey
Kevin Petrecca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Institution for the Advancement of Learning
Original Assignee
Royal Institution for the Advancement of Learning
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Institution for the Advancement of Learning filed Critical Royal Institution for the Advancement of Learning
Publication of AU2011256098A1 publication Critical patent/AU2011256098A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2011256098A 2010-05-18 2011-05-18 Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas Abandoned AU2011256098A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34575110P 2010-05-18 2010-05-18
US61/345,751 2010-05-18
PCT/CA2011/000591 WO2011143762A1 (en) 2010-05-18 2011-05-18 Method for reducing expression of downregulated iν renal cell carcinoma iν malignant gliomas

Publications (1)

Publication Number Publication Date
AU2011256098A1 true AU2011256098A1 (en) 2013-01-10

Family

ID=44991131

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011256098A Abandoned AU2011256098A1 (en) 2010-05-18 2011-05-18 Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas

Country Status (7)

Country Link
US (2) US8765708B2 (https=)
EP (1) EP2571989A4 (https=)
JP (1) JP2013534410A (https=)
CN (1) CN103370414A (https=)
AU (1) AU2011256098A1 (https=)
CA (1) CA2836315A1 (https=)
WO (1) WO2011143762A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075233A1 (en) * 2011-11-21 2013-05-30 The Royal Institution For The Advancement Of Learning / Mcgill University Method for treating brain cancer
RU2747822C2 (ru) * 2016-03-14 2021-05-14 Ф. Хоффманн-Ля Рош Аг Олигонуклеотиды для понижения экспрессии pd-l1
WO2019154884A1 (en) * 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
US12104152B2 (en) 2018-03-19 2024-10-01 The Trustees Of The University Of Pennsylvania 2′F-ANA-LET7 mediated utrophin upregulation for DMD therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704836D0 (sv) * 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
US20070048738A1 (en) * 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
EP1737957A1 (en) * 2004-04-22 2007-01-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem UNIVERSAL TARGET SEQUENCES FOR siRNA GENE SILENCING
EP1815021A2 (en) * 2004-11-03 2007-08-08 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
CN101474413A (zh) * 2009-02-10 2009-07-08 四川大学 Drr1基因在制备抗肿瘤药物中的用途

Also Published As

Publication number Publication date
US9493772B2 (en) 2016-11-15
CA2836315A1 (en) 2011-11-24
JP2013534410A (ja) 2013-09-05
US20130197057A1 (en) 2013-08-01
EP2571989A1 (en) 2013-03-27
CN103370414A (zh) 2013-10-23
WO2011143762A1 (en) 2011-11-24
US20140343124A1 (en) 2014-11-20
EP2571989A4 (en) 2014-08-13
US8765708B2 (en) 2014-07-01

Similar Documents

Publication Publication Date Title
JP6902570B2 (ja) 修飾型ｒｎａ（ｍｏｄ−ｒｎａ）を使用する効率的なインビボタンパク質発現
CN102046810B (zh) 血管生成抑制
WO2013173307A1 (en) Multi-target modulation for treating fibrosis and inflammatory conditions
US20100088775A1 (en) Methods of modulating epithelial-mesenchymal transition and mesenchymal-epithelial transition in cells and agents useful for the same
WO2015164818A1 (en) Multiple targeted rnai for the treatment of cancers
WO2012008302A1 (ja) ｍｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
WO2019126524A1 (en) Therapeutic targets for nash-induced hepatocellular carcinoma
EP2723350B1 (en) New uses of nanog inhibitors and related methods
US9493772B2 (en) Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas
EP3134528A1 (en) Multiple targeted rnai for the treatment of cancers
JP2013534410A6 (ja) 悪性神経膠腫においてｄｏｗｎ ｒｅｇｕｌａｔｅｄ ｉｎ ｒｅｎａｌ ｃｅｌｌ ｃａｒｃｉｎｏｍａの発現を減少させる方法
EP3259346A1 (en) P63 inactivation for the treatment of heart failure
US20230287427A1 (en) Inhibition of lncExACT1 to Treat Heart Disease
US20140128450A1 (en) Cancer Therapy
US11566247B2 (en) Modulation of alternative MDM2 splicing
WO2013075233A1 (en) Method for treating brain cancer
KR101913693B1 (ko) SS18-SSX 융합 유전자 특이적 siRNA 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물
AU2015262889A1 (en) Small interfering RNA (siRNA) for the therapy of type 2 (ADO2) autosomal dominant osteopetrosis caused by CLCN7 (ADO2 CLCN7-dependent) gene mutation
WO2011074652A1 (ja) HIF-2αの発現を抑制する核酸
JP2011188849A (ja) 抗腫瘍効果を有するｍｉＲ−７発現プラスミド
WO2021154705A1 (en) Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
KR20210121767A (ko) 스플라이스좀 관련 단백질인 ik의 용도
JP2021153542A (ja) Ｃｂｆ１結合核酸分子およびその用途
Smith An Investigation into the Mechanism of Action of the SMN2 Bifunctional Oligonucleotide and its Application to Reverse the RON Δ165 Pro-Metastatic Splicing Event
JP2018172285A (ja) 細胞内の異常物質蓄積を伴う疾患の治療薬、バイオマーカー、診断薬、並びに、スクリーニング方法

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application